Corneal collagen cross-linking (CXL) treatment can help kids with developmental delays who have keratoconus — a progressive eye disease.
In April 2016, the U.S. Food and Drug Administration approved this treatment already in use in Europe and Asia.
CXL uses riboflavin (vitamin B2) and ultraviolet light to stop the progression of this blinding eye disease.
UPMC Children's Hospital of Pittsburgh offers CXL treatment at our Center for Collagen Cross-Linking.
Why Choose Children's for Collagen Cross-Linking?
Our center is the first in the state able to treat progressive keratoconus in children, teens, and adults with developmental issues.
Experts at our Division of Pediatric Ophthalmology and the UPMC Eye Center have a strong reputation for complex corneal work. This includes corneal transplant and amniotic membrane transplant.
Contact Us About Collagen Cross-Linking Treatment
